Anti-VEGF

Francesco Bandello, M. Battaglia Parodi, A. J. Augustin, P. Iacono, R. O. Schlingemann, U. Schmidt-Erfurth, F. D. Verbraak

Research output: Book/ReportBook

Abstract

The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.

Original languageEnglish
PublisherS. Karger AG
Number of pages144
ISBN (Print)9783805595308, 9783805595292
DOIs
Publication statusPublished - Aug 13 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Anti-VEGF'. Together they form a unique fingerprint.

  • Cite this

    Bandello, F., Parodi, M. B., Augustin, A. J., Iacono, P., Schlingemann, R. O., Schmidt-Erfurth, U., & Verbraak, F. D. (2010). Anti-VEGF. S. Karger AG. https://doi.org/10.1159/isbn.978-3-8055-9530-8